Skip to main content
    N

    Neurogene Inc (NGNE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $23.30
    -0.63 (-2.63%)

    Market Cap: $495.37M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Neurogene Inc (NGNE) Financials: Revenue, Profit and Cash Flow

    Updated Nov 9, 2026. Financial statements from company filings, amounts in US dollars.

    Neurogene reported revenue of $0 for the fiscal year ended Dec 31, 2025, down 100.0% from the year before. That year, net income was -$90.35M, operating cash flow was -$77.17M and free cash flow was -$78.36M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$29.02M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $103.33M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0-100.0%N/AN/AN/A
    Dec 2024$925.00KN/A100.0%-8930.3%-8123.7%
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0-100.0%N/AN/AN/A
    Dec 2018$25.00MN/A100.0%-130.5%-126.3%
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$925.00K$0$0$0$0$0$25.00M$0$0
    Gross profit$0$925.00K$0$0$0$0$0$25.00M$0$0
    Research and development$75.01M$60.92M$44.39M$47.51M$39.16M$24.34M$52.13M$41.79M$36.27M$28.38M
    Operating income-$103.33M-$82.61M-$55.58M-$56.52M-$60.70M-$33.73M-$70.96M-$32.62M-$51.12M-$37.65M
    Net income-$90.35M-$75.14M-$36.32M-$55.19M-$60.69M-$33.28M-$69.44M-$31.59M-$50.18M-$37.00M
    EBITDAN/AN/A-$52.42M-$53.32M-$58.43M-$31.46M-$68.91M-$31.29M-$49.82M-$37.00M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0-$925.00K$0$925.00K$0$0
    Gross profit$0$0$0-$787.00K$0$0$0-$15.35M$0$925.00K$0-$12.18M
    Operating income-$32.38M-$36.67M-$33.35M-$27.53M-$23.80M-$26.08M-$25.92M-$21.51M-$22.18M-$20.13M-$18.78M-$14.73M
    Net income-$29.02M-$34.49M-$30.93M-$24.73M-$20.95M-$22.02M-$22.65M-$19.51M-$20.22M-$18.49M-$16.92M$2.38M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $3.06M by $100.78M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$288.60M$335.73M$222.57M$109.27M$163.26M$210.52M$147.02M$77.62M$110.33M$154.38M
    Current assets$271.77M$315.92M$200.35M$84.72M$143.99M$194.52M$143.60M$77.17M$108.83M$103.48M
    Cash and equivalents$103.84M$136.59M$148.21M$82.02M$142.47M$192.56M$143.09M$76.93M$52.03M$32.30M
    Total liabilities$23.72M$25.36M$36.55M$10.64M$20.40M$19.30M$5.34M$4.95M$11.44M$9.72M
    Short-term debt$3.06M$3.00M$2.88M$702.00K$1.83M$708.00K$618.00KN/AN/AN/A
    Shareholder equity$264.89M$310.38M$186.02M-$145.74M$142.86M$191.22M$141.69M$72.67M$98.89M$144.66M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$377.90M$244.36M$263.14M$289.18M$287.83M$297.32M$315.30M$335.73M$164.12M$179.82M$195.35M$222.57M
    Total liabilities$23.11M$27.23M$25.36M$24.29M$22.29M$24.06M$23.51M$25.36M$26.71M$24.81M$24.57M$36.55M
    Cash and equivalents$78.94M$112.48M$124.16M$103.84M$71.00M$58.81M$70.77M$136.59M$66.63M$111.03M$150.14M$148.21M
    Shareholder equity$354.79M$217.13M$237.78M$264.89M$265.54M$273.25M$291.80M$310.38M$137.41M$155.01M$170.78M$186.02M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$77.17M-$70.60M-$51.42M-$52.82M-$47.56M-$24.57M-$15.39M-$31.58M-$44.72M-$30.23M
    Capital expenditures$1.18M$808.00K$321.00K$2.23M$3.26M$2.22M$879.00K$49.00K$494.00K$713.00K
    Free cash flow-$78.36M-$71.41M-$51.74M-$55.05M-$50.82M-$26.79M-$16.27M-$31.63M-$45.21M-$30.94M
    Dividends paid$0$2.85M$0N/AN/AN/AN/AN/AN/AN/A
    Share repurchases$241.00K$0N/AN/AN/A$355.00K$352.00KN/AN/A$4.69M
    Investing cash flow$14.00M-$125.26M$25.64M-$2.23M-$3.26M-$2.22M-$688.00K$55.95M$64.01M-$48.06M
    Financing cash flow$30.43M$184.07M$92.48M$66.53M$732.00K$77.14M$82.24M$570.00K$423.00K$71.11M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$29.14M-$23.76M-$26.12M-$17.43M-$19.51M-$19.46M-$20.77M-$17.50M-$15.56M-$15.89M-$21.65M-$16.97M
    Capital expenditures$315.00K$354.00K$281.00K$128.00K$127.00K$148.00K$780.00K$116.00K$167.00K$460.00K$65.00K$128.00K
    Free cash flow-$29.46M-$24.11M-$26.40M-$17.56M-$19.64M-$19.61M-$21.55M-$17.61M-$15.73M-$16.35M-$21.71M-$17.10M
    Last 12 quarters

    Frequently Asked Questions About NGNE

    What is Neurogene's annual revenue?

    Neurogene reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    How fast is Neurogene's revenue growing?

    Revenue was down 100.0% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Neurogene profitable?

    No. Neurogene reported net income of -$90.35M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does NGNE generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$77.17M minus capital expenditures of $1.18M produced free cash flow of -$78.36M.

    How much debt does Neurogene have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $3.06M and cash and equivalents of $103.84M.